A non-conserved amino acid variant regulates differential signalling between human and mouse CD28

Nicla Porciello; Paola Grazioli; Antonio F. Campese; Martina Kunkl; Silvana Caristi; Marta Mastrogiovanni; Michela Muscolini; Francesca Spadaro; Cédric Favre; Jacques A. Nunès; Aldo Borroto; Balbino Alarcon; Isabella Screpanti; Loretta Tuosto

doi:10.1038/s41467-018-03385-8

A non-conserved amino acid variant regulates differential signalling between human and mouse CD28

Nicla Porciello, Paola Grazioli, Antonio F. Campese, Martina Kunkl, Silvana Caristi, Marta Mastrogiovanni, Michela Muscolini, Francesca Spadaro, Cédric Favre, Jacques A. Nunès, Aldo Borroto, Balbino Alarcon, Isabella Screpanti, Loretta Tuosto

Istituto Superiore di Sanita'

Research output: Contribution to journal › Article

Abstract

CD28 superagonistic antibodies (CD28SAb) can preferentially activate and expand immunosuppressive regulatory T cells (Treg) in mice. However, pre-clinical trials assessing CD28SAbs for the therapy of autoimmune diseases reveal severe systemic inflammatory response syndrome in humans, thereby implying the existence of distinct signalling abilities between human and mouse CD28. Here, we show that a single amino acid variant within the C-terminal proline-rich motif of human and mouse CD28 (P²¹² in human vs. A²¹⁰ in mouse) regulates CD28-induced NF-κB activation and pro-inflammatory cytokine gene expression. Moreover, this Y²⁰⁹APP²¹² sequence in humans is crucial for the association of CD28 with the Nck adaptor protein for actin cytoskeleton reorganisation events necessary for CD28 autonomous signalling. This study thus unveils different outcomes between human and mouse CD28 signalling to underscore the importance of species difference when transferring results from preclinical models to the bedside.

Original language	English
Article number	1080
Journal	Nature Communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-03385-8
Publication status	Published - Dec 1 2018

Fingerprint

ASJC Scopus subject areas

Chemistry(all)
Biochemistry, Genetics and Molecular Biology(all)
Physics and Astronomy(all)

Cite this

Porciello, N., Grazioli, P., Campese, A. F., Kunkl, M., Caristi, S., Mastrogiovanni, M., Muscolini, M., Spadaro, F., Favre, C., Nunès, J. A., Borroto, A., Alarcon, B., Screpanti, I., & Tuosto, L. (2018). A non-conserved amino acid variant regulates differential signalling between human and mouse CD28. Nature Communications, 9(1), [1080]. https://doi.org/10.1038/s41467-018-03385-8

A non-conserved amino acid variant regulates differential signalling between human and mouse CD28. / Porciello, Nicla; Grazioli, Paola; Campese, Antonio F.; Kunkl, Martina; Caristi, Silvana; Mastrogiovanni, Marta; Muscolini, Michela; Spadaro, Francesca; Favre, Cédric; Nunès, Jacques A.; Borroto, Aldo; Alarcon, Balbino; Screpanti, Isabella; Tuosto, Loretta.

In: Nature Communications, Vol. 9, No. 1, 1080, 01.12.2018.

Research output: Contribution to journal › Article

Porciello, N, Grazioli, P, Campese, AF, Kunkl, M, Caristi, S, Mastrogiovanni, M, Muscolini, M, Spadaro, F, Favre, C, Nunès, JA, Borroto, A, Alarcon, B, Screpanti, I & Tuosto, L 2018, 'A non-conserved amino acid variant regulates differential signalling between human and mouse CD28', Nature Communications, vol. 9, no. 1, 1080. https://doi.org/10.1038/s41467-018-03385-8

Porciello, Nicla ; Grazioli, Paola ; Campese, Antonio F. ; Kunkl, Martina ; Caristi, Silvana ; Mastrogiovanni, Marta ; Muscolini, Michela ; Spadaro, Francesca ; Favre, Cédric ; Nunès, Jacques A. ; Borroto, Aldo ; Alarcon, Balbino ; Screpanti, Isabella ; Tuosto, Loretta. / A non-conserved amino acid variant regulates differential signalling between human and mouse CD28. In: Nature Communications. 2018 ; Vol. 9, No. 1.

@article{0953511f5a534d95a8373cc7ae76cf61,

title = "A non-conserved amino acid variant regulates differential signalling between human and mouse CD28",

abstract = "CD28 superagonistic antibodies (CD28SAb) can preferentially activate and expand immunosuppressive regulatory T cells (Treg) in mice. However, pre-clinical trials assessing CD28SAbs for the therapy of autoimmune diseases reveal severe systemic inflammatory response syndrome in humans, thereby implying the existence of distinct signalling abilities between human and mouse CD28. Here, we show that a single amino acid variant within the C-terminal proline-rich motif of human and mouse CD28 (P212 in human vs. A210 in mouse) regulates CD28-induced NF-κB activation and pro-inflammatory cytokine gene expression. Moreover, this Y209APP212 sequence in humans is crucial for the association of CD28 with the Nck adaptor protein for actin cytoskeleton reorganisation events necessary for CD28 autonomous signalling. This study thus unveils different outcomes between human and mouse CD28 signalling to underscore the importance of species difference when transferring results from preclinical models to the bedside.",

author = "Nicla Porciello and Paola Grazioli and Campese, {Antonio F.} and Martina Kunkl and Silvana Caristi and Marta Mastrogiovanni and Michela Muscolini and Francesca Spadaro and C{\'e}dric Favre and Nun{\`e}s, {Jacques A.} and Aldo Borroto and Balbino Alarcon and Isabella Screpanti and Loretta Tuosto",

year = "2018",

month = dec

day = "1",

doi = "10.1038/s41467-018-03385-8",

language = "English",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "NLM (Medline)",

number = "1",

}

TY - JOUR

T1 - A non-conserved amino acid variant regulates differential signalling between human and mouse CD28

AU - Porciello, Nicla

AU - Grazioli, Paola

AU - Campese, Antonio F.

AU - Kunkl, Martina

AU - Caristi, Silvana

AU - Mastrogiovanni, Marta

AU - Muscolini, Michela

AU - Spadaro, Francesca

AU - Favre, Cédric

AU - Nunès, Jacques A.

AU - Borroto, Aldo

AU - Alarcon, Balbino

AU - Screpanti, Isabella

AU - Tuosto, Loretta

PY - 2018/12/1

Y1 - 2018/12/1

N2 - CD28 superagonistic antibodies (CD28SAb) can preferentially activate and expand immunosuppressive regulatory T cells (Treg) in mice. However, pre-clinical trials assessing CD28SAbs for the therapy of autoimmune diseases reveal severe systemic inflammatory response syndrome in humans, thereby implying the existence of distinct signalling abilities between human and mouse CD28. Here, we show that a single amino acid variant within the C-terminal proline-rich motif of human and mouse CD28 (P212 in human vs. A210 in mouse) regulates CD28-induced NF-κB activation and pro-inflammatory cytokine gene expression. Moreover, this Y209APP212 sequence in humans is crucial for the association of CD28 with the Nck adaptor protein for actin cytoskeleton reorganisation events necessary for CD28 autonomous signalling. This study thus unveils different outcomes between human and mouse CD28 signalling to underscore the importance of species difference when transferring results from preclinical models to the bedside.

AB - CD28 superagonistic antibodies (CD28SAb) can preferentially activate and expand immunosuppressive regulatory T cells (Treg) in mice. However, pre-clinical trials assessing CD28SAbs for the therapy of autoimmune diseases reveal severe systemic inflammatory response syndrome in humans, thereby implying the existence of distinct signalling abilities between human and mouse CD28. Here, we show that a single amino acid variant within the C-terminal proline-rich motif of human and mouse CD28 (P212 in human vs. A210 in mouse) regulates CD28-induced NF-κB activation and pro-inflammatory cytokine gene expression. Moreover, this Y209APP212 sequence in humans is crucial for the association of CD28 with the Nck adaptor protein for actin cytoskeleton reorganisation events necessary for CD28 autonomous signalling. This study thus unveils different outcomes between human and mouse CD28 signalling to underscore the importance of species difference when transferring results from preclinical models to the bedside.

UR - http://www.scopus.com/inward/record.url?scp=85044238727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044238727&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03385-8

DO - 10.1038/s41467-018-03385-8

M3 - Article

C2 - 29540686

AN - SCOPUS:85044238727

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 1080

ER -

Access to Document

10.1038/s41467-018-03385-8